OKYO Pharma (OKYO) Competitors $1.06 +0.01 (+0.47%) (As of 12/24/2024 01:48 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestTrends OKYO vs. ATOS, IFRX, ENTA, CABA, VXRT, NLTX, PLX, APLT, SAVA, and IVAShould you be buying OKYO Pharma stock or one of its competitors? The main competitors of OKYO Pharma include Atossa Therapeutics (ATOS), InflaRx (IFRX), Enanta Pharmaceuticals (ENTA), Cabaletta Bio (CABA), Vaxart (VXRT), Neoleukin Therapeutics (NLTX), Protalix BioTherapeutics (PLX), Applied Therapeutics (APLT), Cassava Sciences (SAVA), and Inventiva (IVA). These companies are all part of the "pharmaceutical products" industry. OKYO Pharma vs. Atossa Therapeutics InflaRx Enanta Pharmaceuticals Cabaletta Bio Vaxart Neoleukin Therapeutics Protalix BioTherapeutics Applied Therapeutics Cassava Sciences Inventiva OKYO Pharma (NASDAQ:OKYO) and Atossa Therapeutics (NASDAQ:ATOS) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, risk, earnings, profitability, institutional ownership, media sentiment, valuation, dividends and community ranking. Which has more volatility & risk, OKYO or ATOS? OKYO Pharma has a beta of -0.19, indicating that its stock price is 119% less volatile than the S&P 500. Comparatively, Atossa Therapeutics has a beta of 1.22, indicating that its stock price is 22% more volatile than the S&P 500. Do insiders & institutionals believe in OKYO or ATOS? 3.0% of OKYO Pharma shares are held by institutional investors. Comparatively, 12.7% of Atossa Therapeutics shares are held by institutional investors. 40.5% of OKYO Pharma shares are held by company insiders. Comparatively, 7.6% of Atossa Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Do analysts prefer OKYO or ATOS? OKYO Pharma presently has a consensus price target of $7.00, indicating a potential upside of 557.28%. Atossa Therapeutics has a consensus price target of $7.00, indicating a potential upside of 579.61%. Given Atossa Therapeutics' higher possible upside, analysts clearly believe Atossa Therapeutics is more favorable than OKYO Pharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score OKYO Pharma 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Atossa Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is OKYO or ATOS more profitable? OKYO Pharma's return on equity of 0.00% beat Atossa Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets OKYO PharmaN/A N/A N/A Atossa Therapeutics N/A -35.74%-33.51% Does the media refer more to OKYO or ATOS? In the previous week, Atossa Therapeutics' average media sentiment score of 1.00 beat OKYO Pharma's score of 0.00 indicating that Atossa Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment OKYO Pharma Neutral Atossa Therapeutics Positive Which has higher valuation & earnings, OKYO or ATOS? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOKYO PharmaN/AN/A-$16.83MN/AN/AAtossa TherapeuticsN/AN/A-$30.09M-$0.22-4.68 Does the MarketBeat Community believe in OKYO or ATOS? Atossa Therapeutics received 231 more outperform votes than OKYO Pharma when rated by MarketBeat users. However, 100.00% of users gave OKYO Pharma an outperform vote while only 65.12% of users gave Atossa Therapeutics an outperform vote. CompanyUnderperformOutperformOKYO PharmaOutperform Votes8100.00% Underperform VotesNo VotesAtossa TherapeuticsOutperform Votes23965.12% Underperform Votes12834.88% SummaryAtossa Therapeutics beats OKYO Pharma on 6 of the 11 factors compared between the two stocks. Ad Crypto 101 MediaTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… YES, I WANT THE #1 CRYPTO NOW Get OKYO Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for OKYO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OKYO vs. The Competition Export to ExcelMetricOKYO PharmaBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$36.04M$2.96B$5.23B$9.28BDividend YieldN/A1.91%5.12%4.28%P/E RatioN/A46.4687.7717.30Price / SalesN/A417.621,168.55119.64Price / CashN/A174.7643.2337.83Price / Book-5.333.924.834.94Net Income-$16.83M-$42.00M$120.63M$225.49M7 Day Performance-0.47%3.86%2.84%4.14%1 Month Performance1.43%-0.23%19.70%1.16%1 Year Performance-40.17%18.83%30.57%17.01% OKYO Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OKYOOKYO Pharma1.6055 of 5 stars$1.07+0.5%$7.00+557.3%-40.2%$36.04MN/A0.007ATOSAtossa Therapeutics1.5616 of 5 stars$1.08-3.7%$7.00+548.7%+32.1%$135.74MN/A-5.208Positive NewsIFRXInflaRx2.4396 of 5 stars$2.30-2.5%$8.00+247.8%+46.8%$135.43M$168,498.00-2.1960Positive NewsENTAEnanta Pharmaceuticals4.0438 of 5 stars$6.31+4.6%$19.50+209.0%-33.3%$133.73M$67.64M-1.10145Analyst ForecastAnalyst RevisionNews CoverageHigh Trading VolumeCABACabaletta Bio2.668 of 5 stars$2.72-3.5%$26.25+865.1%-89.4%$132.95MN/A-1.3150VXRTVaxart2.0234 of 5 stars$0.58-2.0%$3.00+417.3%+4.1%$131.92M$20.14M-1.44109NLTXNeoleukin TherapeuticsN/A$13.96+1.5%N/A+46.1%$131.20MN/A-7.5690PLXProtalix BioTherapeuticsN/A$1.75-2.8%N/A-1.1%$128.85M$65.49M-13.81200APLTApplied Therapeutics4.5142 of 5 stars$1.11-3.9%$6.60+497.3%-72.7%$128.58M$9.99M-0.7130Analyst DowngradeGap DownSAVACassava Sciences4.4717 of 5 stars$2.66-3.3%$111.50+4,091.7%-90.2%$127.97MN/A-1.9930IVAInventiva2.6224 of 5 stars$2.39-2.4%$13.25+454.4%-51.3%$125.42M$15.62M0.00100News CoverageGap Down Related Companies and Tools Related Companies ATOS Alternatives IFRX Alternatives ENTA Alternatives CABA Alternatives VXRT Alternatives NLTX Alternatives PLX Alternatives APLT Alternatives SAVA Alternatives IVA Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:OKYO) was last updated on 12/25/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredWe recommended Palantir in 2021, now we’re recommending this...My research indicates there is only one investment that can meet AI's unprecedented demand for energy.Behind the Markets | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding OKYO Pharma Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share OKYO Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free OKYO Stock Alerts